By Doug Macron

While Santaris Pharma's efforts with microRNA-targeting therapeutics have primarily been based on its standard locked nucleic acid technology, the company is also testing smaller LNA molecules, dubbed tiny LNAs, designed to inhibit entire miRNA families.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Harvard Medical School's George Church discusses editing human DNA, including germline DNA, in the New England Journal of Medicine.

According to Nature News, the African Academy of Sciences is launching an open-access publishing platform next year.